NCCN Guidelines Insights: Breast Cancer, Version 3.2018. Journal of the National Comprehensive Cancer Network : JNCCN Goetz, M. P., Gradishar, W. J., Anderson, B. O., Abraham, J. n., Aft, R. n., Allison, K. H., Blair, S. L., Burstein, H. J., Dang, C. n., Elias, A. D., Farrar, W. B., Giordano, S. H., Goldstein, L. J., Isakoff, S. J., Lyons, J. n., Marcom, P. K., Mayer, I. A., Moran, M. S., Mortimer, J. n., O'Regan, R. M., Patel, S. A., Pierce, L. J., Reed, E. C., Rugo, H. S., Sitapati, A. n., Smith, K. L., Smith, M. L., Soliman, H. n., Telli, M. L., Ward, J. H., Young, J. S., Shead, D. A., Kumar, R. n. 2019; 17 (2): 118–26

Abstract

These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor-positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.

View details for PubMedID 30787125